Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
BUSINESS
Sumitomo Eyes Conditional Nod for iPS Cell Therapy for Parkinson’s in FY2025
Sumitomo Pharma expects to obtain conditional and time-limited approval in Japan for raguneprocel, its allogeneic iPS cell-derived dopaminergic neural progenitor cell therapy, by the end of FY2025, President and CEO Toru Kimura said on August 6. “If things go smoothly,…
To read the full story
Related Article
- Sumitomo Half-Year Sales Climb 17% on US Growth, FY2026 Outlook Raised
November 2, 2026
- Sumitomo Notches Record Profit on Strong North America Growth
May 14, 2026
- Sumitomo Pharma Sees iPSC Therapy as Potential US$1 Billion Global Product
February 18, 2026
- Sumitomo Flags Diabetes Pipeline Gap as Key Strategic Issue: CEO
February 2, 2026
- Sumitomo within Striking Distance of 250-Billion-Yen Goal for 3 Key Drugs
November 4, 2025
BUSINESS
- Daiichi Sankyo H1 Revenue Zooms 20% as ADCs Drive Growth
November 2, 2026
- Meiji Pharma Wins Defamation Suit over Kostaive Remarks
November 2, 2026
- Senju Licenses Late-Stage CRAO Drug to Kiora in Ex-Asia Deal
November 2, 2026
- Towa Pushes Back Tanabe Factory Buyout by One Month
November 2, 2026
- Fatal Drug Mix-Up Prompts Safety Alert on Two Amphotericin B Products
November 2, 2026
The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…